Amryt Pharma PLC Markus Ziener appointed as Non-Executive Director (1349C)
June 27 2016 - 2:00AM
UK Regulatory
TIDMAMYT
RNS Number : 1349C
Amryt Pharma PLC
27 June 2016
27 June, 2015
Amryt Pharma plc
("Amryt" or the "Company")
Markus Ziener appointed as Non-Executive Director
Amryt Pharma plc (AIM: AMYT, ESM: AYP), the clinical stage
specialty pharma company focused on best in class treatments for
orphan diseases, announces the appointment of Markus Ziener as
Non-Executive Director with immediate effect. Mr Ziener is Chief
Financial Officer of Software AG Stiftung.
Mr Ziener joined Software AG Stiftung in 2013 as a Director of
Asset Management becoming Chief Financial Officer in August 2014.
Prior to joining Software AG Stiftung, a 20.9% shareholder in
Amryt, Mr Ziener worked in a number of senior roles across a broad
range of industries.
Harry Stratford, Chairman of Amryt, said "I am delighted to
welcome Markus to the Board of Amryt. As the Director of Asset
Management within Software AG Stiftung, Markus has been a long term
supporter of the Birken business and was Chairman of the
Supervisory Board until the Company's recent acquisition by Amryt.
In this role, Markus was ultimately responsible for funding the
development of our lead product, Episalvan, which has recently been
approved in January by the European regulatory authorities for the
treatment of partial thickness wounds. Together with our existing
Imlan product range and the opportunity to also develop Episalvan
in the rare disease Epidermolysis Bullosa, we are particularly
excited about the future potential for the Amryt business."
Additional Information required under the AIM rules for
Companies:
The following information is disclosed under Schedule Two
paragraph (g) of the AIM Rules.
(i) Markus Ziener, 50, is currently a director of Software AG Stiftung.
(ii) Within the last 5 years, he has also served as a director of the following companies:
Handelskontor Willmann für Naturprodukte
GmbH
GeckoGroup AG
Markus Ziener has confirmed that there is no other additional
information to be disclosed under Schedule Two paragraph (g) of the
AIM Rules.
Enquiries:
Amryt Pharma plc C/o FTI Consulting
Joe Wiley, CEO
Rory Nealon, CFO/COO
+44 (0) 20
Shore Capital 7408 4090
Nomad and Joint Broker
Bidhi Bhoma, Edward Mansfield
+353 (1) 679
Davy 6363
ESM Adviser and Joint
Broker
John Frain, Anthony Farrell
+44 (0) 20
Stifel 7710 7600
Joint Broker
Jonathan Senior, Ben
Maddison
+44 (0) 20
FTI Consulting 3727 1000
Simon Conway, Brett Pollard
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or 'orphan' diseases. The Company
is building a diversified portfolio of commercially attractive,
best-in-class, propriety new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
Amryt's lead product, Episalvan(R), received marketing approval
for the treatment of partial-thickness wounds from the European
Commission in January 2016. Amryt intends to further develop
Episalvan(R) as a new treatment for Epidermolysis Bullosa ("EB"), a
rare and distressing genetic skin disorder affecting young children
for which there is currently no treatment. Amryt is currently
planning a phase III study of Episalvan(R) in EB, which has been
granted US and EU orphan drug designation.
Amryt's earlier stage products are focused on developing novel,
next generation somatostatin analogue ("SSA") peptide medicines for
patients with rare neuroendocrine diseases, where there is a high
unmet medical need. These include acromegaly and Cushing's
disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAEXLFLQQFZBBQ
(END) Dow Jones Newswires
June 27, 2016 02:00 ET (06:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024